GlassScriptPhysician profile
Daniel J Durocher
NPI 1720529209
$5,175.41
in general payments reported to CMS, 2019-2025
40 companies · $95.26 in 2025
The $95.26 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $552 · 2021: $2,424 · 2022: $1,830 · 2023: $30.00 · 2024: $49.34 · 2025: $95.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $174.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $618.54 | 2019-2022 | |
| Abbvie INC. | $593.95 | 2020-2023 | Qulipta, Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $398.58 | 2021 | |
| Novo Nordisk INC | $355.56 | 2020-2022 | |
| Esperion Therapeutics, INC. | $338.45 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.99 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $290.46 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $247.45 | 2020-2021 | |
| Pfizer INC. | $243.99 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $220.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $204.60 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.30 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $167.12 | 2020-2022 | |
| Glaxosmithkline, LLC. | $79.73 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $76.30 | 2021-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $66.00 | 2022-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $62.68 | 2021 | |
| Sanofi-Aventis U.S. LLC | $56.69 | 2022 | |
| Smith+Nephew, INC. | $52.99 | 2024-2025 | Collagenase Santyl |
| Ets Wound Care LLC | $47.76 | 2025 | Mirragen Advanced Wound Matrix |
| Allergan, INC. | $47.14 | 2020 | |
| Amgen INC. | $45.10 | 2020-2022 | |
| Biogen, INC. | $38.93 | 2021 | |
| Eisai INC. | $37.01 | 2020 | |
| Janssen Pharmaceuticals, INC | $32.66 | 2022 | |
| Merck Sharp & Dohme LLC | $30.30 | 2021-2022 | |
| Organogenesis INC. | $29.47 | 2025 | Apligraf |
| Vanda Pharmaceuticals INC. | $28.25 | 2022 | |
| Daiichi Sankyo INC. | $27.44 | 2020 | |
| Axsome Therapeutics, INC. | $25.84 | 2022 | |
| Eyevance Pharmaceuticals LLC | $25.33 | 2021 | |
| Hikma Pharmaceuticals USA | $25.33 | 2021 | |
| Alnylam Pharmaceuticals INC. | $24.88 | 2022 | |
| Genentech USA, INC. | $23.74 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.23 | 2022 | |
| Shionogi INC | $16.72 | 2019 | |
| Amarin Pharma, INC. | $15.69 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.38 | 2021 | |
| Dexcom, INC. | $13.88 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Durocher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.